BIOXX Pharmaceuticals

Coming Soon....
GelGuard 120ml

Oropharyngeal mucositis is an acute and distressing toxic effect of chemotherapy and head and neck irradiation. This oral sequela significantly impairs the daily functioning and quality of life of patients.

Coming Soon....

Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern

The Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) is an independent group of experts that periodically monitors and evaluates the evolution of SARS-CoV-2 and assesses if specific mutations and combinations of mutations alter the behaviour of the virus. The TAG-VE was convened on 26 November 2021 to assess the SARS-CoV-2 variant: B.1.1.529.

The B.1.1.529 variant was first reported to WHO from South Africa on 24 November 2021. The epidemiological situation in South Africa has been characterized by three distinct peaks in reported cases, the latest of which was predominantly the Delta variant. In recent weeks, infections have increased steeply, coinciding with the detection of B.1.1.529 variant. The first known confirmed B.1.1.529 infection was from a specimen collected on 9 November 2021.

This variant has a large number of mutations, some of which are concerning. Preliminary evidence suggests an increased risk of reinfection with this variant, as compared to other VOCs. The number of cases of this variant appears to be increasing in almost all provinces in South Africa. Current SARS-CoV-2 PCR diagnostics continue to detect this variant. Several labs have indicated that for one widely used PCR test, one of the three target genes is not detected (called S gene dropout or S gene target failure) and this test can therefore be used as marker for this variant, pending sequencing confirmation. Using this approach, this variant has been detected at faster rates than previous surges in infection, suggesting that this variant may have a growth advantage.

There are a number of studies underway and the TAG-VE will continue to evaluate this variant. WHO will communicate new findings with Member States and to the public as needed.

Based on the evidence presented indicative of a detrimental change in COVID-19 epidemiology, the TAG-VE has advised WHO that this variant should be designated as a VOC, and the WHO has designated B.1.1.529 as a VOC, named Omicron.

As such, countries are asked to do the following:

enhance surveillance and sequencing efforts to better understand circulating SARS-CoV-2 variants.
submit complete genome sequences and associated metadata to a publicly available database, such as GISAID.
report initial cases/clusters associated with VOC infection to WHO through the IHR mechanism.
where capacity exists and in coordination with the international community, perform field investigations and laboratory assessments to improve understanding of the potential impacts of the VOC on COVID-19 epidemiology, severity, effectiveness of public health and social measures, diagnostic methods, immune responses, antibody neutralization, or other relevant characteristics.
Individuals are reminded to take measures to reduce their risk of COVID-19, including proven public health and social measures such as wearing well-fitting masks, hand hygiene, physical distancing, improving ventilation of indoor spaces, avoiding crowded spaces, and getting vaccinated.

For reference, WHO has working definitions for SARS-CoV-2 Variant of Interest (VOI) and Variant of Concern (VOC).

A SARS-CoV-2 VOI is a SARS-CoV-2 variant:

with genetic changes that are predicted or known to affect virus characteristics such as transmissibility, disease severity, immune escape, diagnostic or therapeutic escape; AND
that has been identified as causing significant community transmission or multiple COVID-19 clusters, in multiple countries with increasing relative prevalence alongside increasing number of cases over time, or other apparent epidemiological impacts to suggest an emerging risk to global public health.
A SARS-CoV-2 VOC is a SARS-CoV-2 variant that meets the definition of a VOI (see above) and, through a comparative assessment, has been demonstrated to be associated with one or more of the following changes at a degree of global public health significance:

increase in transmissibility or detrimental change in COVID-19 epidemiology; OR
increase in virulence or change in clinical disease presentation; OR
decrease in effectiveness of public health and social measures or available diagnostics, vaccines, therapeutics

TEMAXA 10mg (Tamoxifen) is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients.This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

October is Breast Cancer Awareness Month, an opportunity to show our support and encouragement to those living with breast cancer and also raise awareness for people in our lives who would benefit from learning about prevention and early detection.

Breast cancer is the most common form of cancer diagnosed in women. Many of us know someone affected by this disease, and this month is a reminder to support those in the fight against breast cancer, celebrate the survivors, honor those who have been taken too soon, and to never give up hope.

*Now time is changed. We are BIOXX Pharmaceuticals with You.*
*Balance your Beauty in October campaign*

.5mg

Balance your Beauty in October campaign
Now time is changed. We are BIOXX Pharmaceuticals with You.


2.5mg

What Can I Do to Reduce My Risk of Breast Cancer?

In Your Difficult time BIOXX Pharmaceuticals with You.


.5mg

Many factors over the course of a lifetime can influence your breast cancer risk. You can’t change some factors, such as getting older or your family history, but you can help lower your risk of breast cancer by taking care of your health in the following ways—

Keep a healthy weight.
Exercise regularly.
Don’t drink alcohol, or limit alcoholic drinks.
If you are taking, or have been told to take, hormone replacement therapyexternal icon or oral contraceptivesexternal icon (birth control pills), ask your doctor about the risks and find out if it is right for you.
Breastfeed your children, if possible.
If you have a family history of breast cancer or inherited changes in your BRCA1 and BRCA2 genes, talk to your doctor about other ways to lower your risk.
Staying healthy throughout your life will lower your risk of developing cancer, and improve your chances of surviving cancer if it occurs.

In Your Difficult time BIOXX Pharmaceuticals with You.

.5mg

What Are the Symptoms of Breast Cancer?

Different people have different symptoms of breast cancer. Some people do not have any signs or symptoms at all.

Some warning signs of breast cancer are—

New lump in the breast or underarm (armpit).
Thickening or swelling of part of the breast.
Irritation or dimpling of breast skin.
Redness or flaky skin in the ni**le area or the breast.
Pulling in of the ni**le or pain in the ni**le area.
Ni**le discharge other than breast milk, including blood.
Any change in the size or the shape of the breast.
Pain in any area of the breast.
Keep in mind that these symptoms can happen with other conditions that are not cancer.

If you have any signs or symptoms that worry you, be sure to see your doctor right away.

Bioxx pharma is a well-known and reputable marketing and Distribution Company which is committed to provide differentiated, high quality and need drugs to our customers. We provide a wide range of prescription drugs describe vaccine and consumer Health Care products. We aim to provide all drug to build a good Health Care systems.

BIOXX Pharmaceuticals updated their phone number.

BIOXX Pharmaceuticals updated their business hours.

BIOXX Pharmaceuticals updated their website address.

It's now easier to contact BIOXX Pharmaceuticals.